{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.62","upperLimit":"0.90","value":"0.74"},{"groupId":"OG001","lowerLimit":"0.77","upperLimit":"0.97","value":"0.87"},{"groupId":"OG002","lowerLimit":"0.70","upperLimit":"0.99","value":"0.84"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"21"}],"units":"Participants"}],"description":"Progression-free survival probability of patients who are alive and without progression 18 months from ASCT, time-to-event","dispersionType":"90% Confidence Interval","groups":[{"description":"Pembrolizumab 200mg IV every 3 weeks up to 8 cycles\n\nPembrolizumab: Anti-PD-1 monoclonal antibody","id":"OG000","title":"Diffuse Large B Cell Lymphoma"},{"description":"Pembrolizumab 200mg IV every 3 weeks up to 8 cycles\n\nPembrolizumab: Anti-PD-1 monoclonal antibody","id":"OG001","title":"Classical Hodgkin Lymphoma"},{"description":"Pembrolizumab 200mg IV every 3 weeks up to 8 cycles\n\nPembrolizumab: Anti-PD-1 monoclonal antibody","id":"OG002","title":"Peripheral T Cell Lymphoma"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"18 months","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"progression-free survival probability"}